Literature DB >> 10495450

5-AZA-2'-deoxycytidine-induced dysmorphogenesis in the rat.

S Branch1, N Chernoff, C Brownie, B M Francis.   

Abstract

5-aza-2'-deoxycytidine (d-AZA) causes temporally related defects in the developing mouse. Treatment of 1.0 mg/kg on gestation day (GD) 8 results in axial skeletal defects; on GD9, cleft palate and vertebral defects; on GD10, hindlimb phocomelia; and on GD11, digital defects. An unusual aspect of d-AZA teratogenicity in mice is that the phocomelia appears to be specific to the hindlimb, and the forelimb is not similarly affected regardless of treatment day. The current study was initiated to evaluate the embryonic response of another species, the rat, to this unique teratogen. Pregnant Sprague Dawley (CD) rats were treated with d-AZA or vehicle control. The compound was administered i.p. on GD9, 10, 11, or 12 to parallel developmental staging of the mouse. The highest dose (1.0 mg/kg) elicited effects indicating increased sensitivity to the compound in the rat as compared to the mouse. GD9 treatment was characterized by massive resorptions; GD10, by a predominance of axial skeletal defects and cleft palate; GD11, by a predominance of forelimb phocomelia and missing ribs; and GD12 by hindlimb phocomelia and forelimb digit defects. These data indicate significant differences in the developmental responses to d-AZA of the mouse and the rat. This may reflect interspecies differences in the temporal expression of genes involved in morphogenesis and/or the methylation patterns of such genes. Molecular data generated in the mouse will be compared to that of the rat to further characterize the developmental dynamics responsible for the interspecies differences. Teratogenesis Carcinog. Mutagen. 19:329-338, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495450

Source DB:  PubMed          Journal:  Teratog Carcinog Mutagen        ISSN: 0270-3211


  3 in total

Review 1.  Developmental epigenetics of the murine secondary palate.

Authors:  Ratnam S Seelan; Partha Mukhopadhyay; M Michele Pisano; Robert M Greene
Journal:  ILAR J       Date:  2012

2.  The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal:  Oncologist       Date:  2016-04-18

3.  MicroRNA-34a is dispensable for p53 function as teratogenesis inducer.

Authors:  Eyal Mor; Lin He; Arkady Torchinsky; Noam Shomron
Journal:  Arch Toxicol       Date:  2014-03-13       Impact factor: 5.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.